CGEM — Cullinan Therapeutics, Inc. stock price, charts and financials

Latest market price

21.08

-0.28-1.31%

Overview Short InterestFilings

CGEMQT91Cullinan Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

21.08-1.31%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

RAPP-3.58%$40.45 GHRS-1.60%$28.26 ZYME-3.31%$26.57 AGIO-1.61%$33.07 ZBIO-1.47%$31.50 GPCR-0.28%$35.00 NUVB-3.62%$5.85 ADMA+1.79%$9.11

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	61.46M	Perf Week	2.38%

Market Cap	1.30B	Forward P/E	-	EPS next Y	-2.60	Insider Trans	-0.13%	Shs Float	44.16M	Perf Month	-6.39%

Enterprise Value	961.53M	PEG	-	EPS next Q	-0.85	Inst Own	-	Short Float	23.49%	Perf Quarter	40.25%

Income	-220.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	11.35	Perf Half Y	61.16%

Sales	0.00	P/B	4.02	EPS next Y	18.07%	ROA	-56.27%	Short Interest	10.37M	Perf YTD	103.67%

Book/sh	5.24	P/C	3.87	EPS next 5Y	-	ROE	-52.89%	52W High	23.19 -9.10%	Perf Year	255.48%

Cash/sh	5.45	P/FCF	-	EPS past 3/5Y	-	ROIC	-68.50%	52W Low	5.68 271.13%	Perf 3Y	113.79%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.54% 4.51%	Perf 5Y	-26.68%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	0.32%	Oper. Margin	0.00%	ATR (14)	1.06	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	8.42	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	52.62	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	8.42	EPS Q/Q	24.30%	SMA20	-2.55%	Beta	-0.04	Target Price	33.50

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	7.34%	Rel Volume	3.92	Prev Close	21.36

Employees	109	LT Debt/Eq	0.00	Earnings	Nov 05	SMA200	39.63%	Avg Volume	828.50K	Price	21.08

IPO Date	Jan 08, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.34% -	Net Debt/EBITDA	0.37	Volume	3,251,008	Change	-1.31%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-14-26	Reiterated	BTIG	Buy	$39 → $40
Aug-17-26	Reiterated	UBS	Buy	$30 → $27
Jul-29-26	Reiterated	BTIG	Buy	$38 → $39
May-08-26	Reiterated	Wedbush	Outperform	$36 → $37
Apr-28-26	Reiterated	HC Wainwright & Co.	Buy	$27 → $30
Mar-11-26	Reiterated	Wedbush	Outperform	$34 → $36
Mar-10-26	Reiterated	Stifel Nicolaus		$28
Feb-02-26	Initiated	Guggenheim	Buy	$30
Jan-08-26	Reiterated	Morgan Stanley	Overweight	$28 → $30
Jan-08-26	Reiterated	HC Wainwright & Co.	Buy	$28 → $27

Latest News· Times ET

Sep-15-26

Sep-15-2612:29AM

Engineers Gate Manager LP Increases Stock Position in Cullinan Therapeutics, Inc. $CGEMdefenseworld.net

Sep-14-26

Sep-14-2601:31PM

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call - SlideshowSeekingAlpha

08:31AM

Cullinan Therapeutics, Inc. (CGEM) Shareholder/Analyst Call Transcriptseekingalpha.com

03:00AM

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancerglobenewswire.com

Sep-13-26

Sep-13-2603:15PM

Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancerbusinesswire.com

Sep-10-26

Sep-10-2609:00AM

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancerglobenewswire.com

Aug-26-26

Aug-26-2601:41AM

Cullinan Therapeutics: A Self-Funding Bridge To Immune Resetseekingalpha.com

12:01AM

Bank of America Corp DE Acquires 170,417 Shares of Cullinan Therapeutics, Inc. $CGEMdefenseworld.net

Aug-19-26

Aug-19-2608:11AM

Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung CancerBenzinga

08:03AM

Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancerbusinesswire.com

Aug-17-26

Aug-17-2602:41AM

HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price TargetBenzinga

Aug-13-26

Aug-13-2607:21AM

Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shapebenzinga.com

Aug-06-26

Aug-06-2608:49AM

Cullinan Therapeutics (NASDAQ:CGEM) Shares Jump on Inline Q2 Earnings and Pipeline MilestonesChartMill

03:00AM

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsglobenewswire.com

Jul-29-26

Jul-29-2602:13AM

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $39Benzinga

Company

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	54	54	42	—	—	—	—	—
Research and Development	187	143	148	—	—	—	—	—
Other Operating Expense	1	0	1	—	—	—	—	—
Operating Income	-242	-197	-191	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	22	29	22	—	—	—	—	—
Net Income Before Taxes	-220	-167	-169	—	—	—	—	—
Income Taxes	0	0	-14	—	—	—	—	—
Consolidated Net Income	-220	-167	-153	—	—	—	—	—
Net Income From Continuing Operations	-220	-168	-155	—	—	—	—	—
Net Income	-220	-167	-153	—	—	—	—	—
EPS (Recurring)	-3.72	-3.11	-3.69	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.72	-3.11	-3.69	—	—	—	—	—
EPS (Diluted)	-3.72	-3.11	-3.69	—	—	—	—	—
EBITDA	-220	-167	-190	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	59	54	42	—	—	—	—	—
Market Capitalization	611	658	428	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Sep 08 '26	Option Exercise	4.30	4,000	17,200	166,844	Sep 10
Michaelson Jennifer	Chief Scientific Officer	Sep 08 '26	Sale	21.57	8,000	172,560	158,844	Sep 10
Michaelson Jennifer	Chief Scientific Officer	Aug 13 '26	Option Exercise	4.30	30,000	129,000	192,844	Aug 14
Michaelson Jennifer	Chief Scientific Officer	Aug 13 '26	Sale	20.26	30,000	607,800	162,844	Aug 14
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Sale	17.82	8,000	142,560	162,844	Jul 07
Michaelson Jennifer	Chief Scientific Officer	Jul 06 '26	Option Exercise	4.30	4,000	17,200	170,844	Jul 07
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Option Exercise	4.30	4,000	17,200	174,844	May 06
Michaelson Jennifer	Chief Scientific Officer	May 05 '26	Sale	14.62	8,000	116,996	166,844	May 06
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Option Exercise	4.30	4,000	17,200	178,844	Mar 09
Michaelson Jennifer	Chief Scientific Officer	Mar 05 '26	Sale	15.68	8,000	125,440	170,844	Mar 09
Michaelson Jennifer	Chief Scientific Officer	Feb 25 '26	Sale	14.14	1,780	25,169	174,844	Feb 26
AHMED NADIM	President and CEO	Feb 24 '26	Sale	14.47	13,515	195,562	390,803	Feb 25
Michaelson Jennifer	Chief Scientific Officer	Feb 24 '26	Sale	14.47	3,601	52,106	176,624	Feb 25
Jones Jeffrey Alan	Chief Medical Officer	Feb 24 '26	Sale	14.47	4,582	66,302	159,968	Feb 25
SUMER JACQUELYN L	Chief Legal Officer	Feb 24 '26	Sale	14.47	3,601	52,106	128,089	Feb 25

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.